193 related articles for article (PubMed ID: 29614442)
21. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
22. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
23. Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model.
Johnson LM; Sykes AD; Lu Z; Valdez JM; Gattuso J; Gerhardt E; Hamilton KV; Harrison LW; Hines-Dowell SJ; Jurbergs N; McGee RB; Nuccio R; Ouma AA; Pritchard M; Quinn EA; Baker JN; Mandrell BN; Nichols KE
Cancer; 2019 Jul; 125(14):2455-2464. PubMed ID: 30901077
[TBL] [Abstract][Full Text] [Related]
24. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
[TBL] [Abstract][Full Text] [Related]
25. Health professionals' practice for young people with, or at risk of, Li-Fraumeni syndrome: An Australasian survey.
Forbes Shepherd R; Keogh LA; Werner-Lin A; Delatycki MB; Forrest LE
J Genet Couns; 2020 Oct; 29(5):737-747. PubMed ID: 31872506
[TBL] [Abstract][Full Text] [Related]
26. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
[TBL] [Abstract][Full Text] [Related]
27. Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
Rosenberg SM; McCue S; He J; Lafky JM; Carey LA; Galanis E; Leonard JP; Meyerhardt J; Ng K; Schwartz GK; Stock W; Paskett ED; Partridge AH; George S
Cancer; 2024 Mar; 130(5):750-769. PubMed ID: 37916800
[TBL] [Abstract][Full Text] [Related]
28. Additional germline findings from a tumor profiling program.
Stjepanovic N; Stockley TL; Bedard PL; McCuaig JM; Aronson M; Holter S; Semotiuk K; Leighl NB; Jang R; Krzyzanowska MK; Oza AM; Gupta A; Elser C; Ahmed L; Wang L; Kamel-Reid S; Siu LL; Kim RH
BMC Med Genomics; 2018 Aug; 11(1):65. PubMed ID: 30092803
[TBL] [Abstract][Full Text] [Related]
29. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.
Goebel EA; Kerkhof J; Dzyubak O; McLachlin CM; McGee J; Sadikovic B
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011309
[TBL] [Abstract][Full Text] [Related]
30. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.
Andoni T; Wiggins J; Robinson R; Charlton R; Sandberg M; Eeles R
Sci Rep; 2022 Feb; 12(1):2507. PubMed ID: 35190596
[TBL] [Abstract][Full Text] [Related]
31. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
[TBL] [Abstract][Full Text] [Related]
32. When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?
DeLeonardis K; Hogan L; Cannistra SA; Rangachari D; Tung N
J Oncol Pract; 2019 Sep; 15(9):465-473. PubMed ID: 31509718
[TBL] [Abstract][Full Text] [Related]
33. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
[TBL] [Abstract][Full Text] [Related]
34. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
[TBL] [Abstract][Full Text] [Related]
35. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.
Carlo MI; Mukherjee S; Mandelker D; Vijai J; Kemel Y; Zhang L; Knezevic A; Patil S; Ceyhan-Birsoy O; Huang KC; Redzematovic A; Coskey DT; Stewart C; Pradhan N; Arnold AG; Hakimi AA; Chen YB; Coleman JA; Hyman DM; Ladanyi M; Cadoo KA; Walsh MF; Stadler ZK; Lee CH; Feldman DR; Voss MH; Robson M; Motzer RJ; Offit K
JAMA Oncol; 2018 Sep; 4(9):1228-1235. PubMed ID: 29978187
[TBL] [Abstract][Full Text] [Related]
37. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
38. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
39. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
40. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
